ISHL12 2022 | Using Hodgkin lymphoma as a model for immuno-oncologic therapeutic approaches in other lymphomas
In this video, Paul Jan Bröckelmann, MD, University Hospital of Cologne, Cologne, Germany, discusses the use of Hodgkin lymphoma (HL) as an immuno-oncologic therapeutic model, highlighting the success of anti-PD1 checkpoint blockade in this disease. Dr Bröckelmann also explains the complicated mechanisms of action involved in HL and checkpoint inhibition, and how understanding these may allow clinicians and researchers to apply immune checkpoint treatment in other lymphoid malignancies. This interview took place at The 12th International Symposium on Hodgkin Lymphoma (ISHL12), held in Cologne, Germany.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Disclosures
Honoraria: BeiGene, Bristol-Myers Squibb, MSD, Takeda
Research funding: BeiGene, Bristol-Myers Squibb, MSD, Takeda
Advisory boards: Takeda
Speakers’ bureau: BeiGene, MSD
